Zur Rose Group: reimbursement by earnings of the purchase price for the selling of medpex

Zur Rose Group: reimbursement by earnings of the purchase price for the selling of medpex

At the end of 2019, the Zur Rose Group and online pharmacy providers medpex agreed to settle the earn-out components for 2019 and 2020 that form part of the purchase price by making a one-off payment of the amount measured in the 2019 provisional financial statements. Medpex’s owners have successfully moved the organization forward since the purchase and reached the development targets agreed. Medpex has the best-in-class online marketing and development expertise and is a perfect addition to the current strategy to increase market share in Germany.

The Zur Rose Group plans to use the founders ‘ expertise for the whole German market as quickly as possible by ending early sales. Consequently, they carry out leadership positions in Germany’s division. They are actively interested in a management sharing scheme to bind them to the Zur Rose Group and will significantly increase their current holdings.

The Swiss Zur Rose Group is Europe’s first e-commerce group and one of the top medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective drug medication, helping to reduce the cost of health care.

It is also marked by the ongoing development of integrated production management systems and actively promotes its position as a comprehensive, unified healthcare cross-service network. The added value development and a clear customer focus make the Group a key strategic partner for service providers, payers and industry.

The Zur Rose Group is involved internationally with its large brands, including Germany’s best-known pharmacy chain DocMorris. The company employs more than 1,300 people at various locations and in fiscal 2018 produced a turnover of CHF 1,207 million. On the SIX Swiss Exchange, the shares of Zur Rose Group AG are listed.